...
机译:P1.03-24 TMPRSS4:NSCLC中的一种新型预后生物标志物和治疗靶标
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
Translational Molecular Pathology The University of Texas MD Anderson Cancer Center Houston;
Translational Molecular Pathology The University of Texas MD Anderson Cancer Center Houston;
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
Program in Solid Tumors Center for Applied Medical Research (CIMA) University of Navarra;
机译:P1.03-24 TMPRSS4:NSCLC中的一种新型预后生物标志物和治疗靶标
机译:非小细胞肺癌靶向治疗的预后和预测性生物标志物:谁为之付出代价?
机译:口腔鳞状细胞癌中的预后生物标志物和治疗靶标:基于跨数据库分析的研究
机译:新型靶阶级:人类疾病和发育miRNA的MicroRNA作为诊断生物标志物和治疗发育的目标 - MicroRNA和疾病发展的前瞻性作用
机译:通过新型研究模型和预后生物标志物改善头颈癌的治疗方法
机译:FAM83A和FAM83B作为NSCLC的预后生物标志物和潜在的新治疗靶标
机译:FAM83A和FAM83B作为预后生物标志物和NSCLC中的潜在新的治疗目标